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Reactivation of the human polyomavirus BK (BKV) has emerged as an important cause of allograft rejection in renal transplant recipients.
Expression of the viral early promoter that leads to production of T-antigen is the first event in viral lytic infection. In an effort to understand
the mechanism involved in the activation of BKVearly gene (BKVE) expression, we analyzed the promoter/enhancer region of the virus and
identified binding motifs for the inducible transcription factors NF-nB and C/EBPh, which are in juxtaposition to each other downstream
from the early gene transcription initiation site. Results from transfection studies demonstrate that overexpression of the p65 subunit of NF-
nB, but not C/EBPh stimulates transcription of the BKVE promoter in CV-1 cells. Interestingly, low level expression of C/EBPh showed a
synergistic effect on p65 activation of the BKVE promoter, suggesting a functional cooperativity between these two regulators upon viral
gene transcription. Results from DNA-binding studies showed the ability of p65 and C/EBPh to bind independently with BKV DNA as
removal of the binding site for p65 or C/EBPh had no significant effect on the interaction of p65 and C/EBPh with their motifs, respectively.
Functional evaluation of the mutant promoter with no binding sites for either NF-nB or C/EBPh showed that the observed synergism requires
the p65 but not the C/EBPh binding site, suggesting cross-talk between C/EBPh and p65 in this event. Results from the co-expression of p65
and C/EBPh showed no evidence for the formation of a DNA–protein complex containing both p65 and C/EBPh, although results from
protein–protein interaction studies verified the ability of C/EBPh to interact with p65. A dominant-negative isoform of C/EBPh which
contains the DNA binding but not activation domain of full-length C/EBPh cooperated with p65 in activating the BKVE promoter,
suggesting a functional interaction between the b-ZIP domain of C/EBPh and NF-nB.
D 2005 Elsevier Inc. All rights reserved.
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for the polyomavirus BK (Hirsch and Steiger, 2003). The
vast majority of the human population is infected asympto-
matically with BKV during early childhood, after which the
virus remains latent in the kidney (West et al., 2001).
Periodically, BKV reactivates to shed virus into the urine
with no apparent loss of kidney function in normal
individuals (Ramos et al., 2004).
In immunosuppressed individuals, such as kidney trans-
plant recipients, bone marrow transplant recipients, and
acquired immunodeficiency syndrome (AIDS) patients,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: kamel.khalili@temple.edu (K. Khalili).uncontrolled reactivation of the virus can lead to serious
complications. Reactivation of BKV leads to the develop-
ment of interstitial nephritis and allograft loss in roughly
8% of renal transplant recipients and hemorrhagic cystitis in
bone marrow transplant patients (Iwamoto et al., 2002;
Ramos et al., 2004). BKV has the potential to reactivate
and cause disseminated infection in AIDS patients, includ-
ing encephalitis, pneumonitis, and atypical retinitis (Hed-
quist et al., 1999; Lesprit et al., 2001; Vallbracht et al.,
1993). In addition, there have been many reports on the
detection of BKV DNA in human tumors by PCR and
Southern blotting. These include Kaposi’s sarcoma, brain
tumors, and tumors of the urinary tract (for a review, see
Corallini et al., 2001).2005) 1–9
Rapid Communication2The genome of BKV is comprised of double-stranded,
circular DNA of approximately 5.2 kb. Like the other
polyomaviruses, BKV contains a variable bidirectional
promoter/enhancer region of about 500 base pairs, which
in one direction controls transcription of the early genes
encoding large and small T-antigens. In the opposite
direction, the BKV promoter/enhancer initiates transcription
of the viral late genome that leads to production of the viral
capsid proteins VP1, VP2, and VP3 and the small auxiliary
Agnoprotein after the onset of viral DNA replication. The
promoter/enhancer region of each BKV strain displays a
high degree of variability that has been explained by
duplications, deletions, and rearrangement of the enhancer
region (Shah, 1996). The promoter/enhancer of archetype
BKV, which predominates in urine and is believed to be the
transmissible form of the virus, consists of a true palindrome
(Pal), two inverted repeats (IR1 and IR2), an approximately
20 base-pair AT-rich region (A/T), and several blocks
designated by the letters P (68 base pair), Q (39 base pair),
R (63 base pair), and S (63 base pair). Each BKV strain
isolated from patient samples contains a unique arrangement
of deleted, duplicated, and/or rearranged P-Q-R-S segments.
For example, the BKV Dunlop enhancer region consists of
P1–68-P1–7;26–68-P1–64-S1–63 arrangement in which the Q and
R segments have been deleted, the P region has been
triplicated, and an 18-base pair segment has been deleted
from the middle P segment (Fig. 1A) (Dorries et al., 1994).
Previous studies using linker scan analysis and DNase
protection assays have identified binding sites for the
transcription factors NF-1 and Sp1 within the BKV
promoter/enhancer (Deyerle and Subramani, 1988; Marko-
witz and Dynan, 1988; for a review, see Moens and Rekvig,
2001). The NF-1 and Sp1 sites are required for efficient
early gene transcription (Deyerle and Subramani, 1988). In
addition to the NF-1 and Sp1 sites, the BKV Dunlop
promoter/enhancer contains an AP-1 site at each P block
junction, which are not present in the BKV archetype.
As a first step in studying transcriptional regulation of the
BKV genome, we analyzed the sequence of the viral DNA
spanning between the early and late gene translations
initiation site by MatInspector (MatInspector). The results
showed that in addition to the previously identified binding
sites for several transcription factors including NF-1, Sp1,
and AP-1, there exist potential binding sites for C/EBPh and
NF-nB within the early leader region immediately upstream
from the early gene initiation codon between nucleotides 9–
22 and 25–34 of the BKV genome, respectively (Fig. 1A).
Examination of the promoter/enhancer of the BKV strains
revealed that this region is highly conserved. Deletion
analysis experiments have demonstrated that BKV early
promoter activity is dependent upon elements that lie within
this region, unlike SV40 where elements in the early leader
sequence are not significantly involved in regulating early
promoter transcription (Moens and Rekvig, 2001).
To determine the functional contribution of NF-nB and
C/EBPh motifs on transcription of the BKVE genome, theDNA fragment corresponding to the BKV Dunlop pro-
moter/enhancer was fused in the early (BKVE) or late
(BKVL) orientations into the BamHI site of pBLCAT3 and
introduced into a monkey kidney cell line (CV-1) (Luckow
and Schutz, 1987). Cells were transfected with the reporter
plasmids in the presence and absence of a plasmid
expressing the functional subunit of NF-nB, p65. As shown
in Fig. 1B, expression of p65 enhanced the level of
transcription of the BKVE promoter (lane 2). To assess the
effect of C/EBPh, we utilized various amounts of plasmid
DNA expressing C/EBPh and found no significant effect on
the transcription of the viral promoter upon expression of C/
EBPh in the cells (lanes 3–6). To assess the possible
cooperativity between C/EBPh and p65, cells were trans-
fected with plasmid expressing p65 and various amounts of
a plasmid expressing C/EBPh. As seen in Fig. 1B, co-
expression of p65 with a low amount of C/EBPh resulted in
synergistic activation of the BKVE promoter, suggesting
that these two proteins can functionally cooperate to
stimulate BKVE transcription (lane 7). It was also noted
that at higher concentrations of C/EBPh, the level of
synergism between p65 and C/EBPh diminished (lanes 8–
10). This effect may be due to squelching of transcription
factors which may occur upon overexpression of proteins in
transient assays. Indeed, one can also envision the involve-
ment of co-factors in the synergism between p65 and C/
EBPh and that the increased levels of C/EBPh may induce
association of these factors off the DNA molecule, thus
causing loss in transcriptional activation of the BKV
promoter. Expression of C/EBPh and p65 was verified by
Western blot in the transfected cells (not shown). Under
similar conditions, expression of p65 and C/EBPh, either
alone or together, repressed the basal transcription of the
BKVL promoter (Fig. 1C). These observations suggest a
differential effect of NF-nB and C/EBPh transcription
factors on the control of viral early and late genes in kidney
cell lines.
Next, we employed electrophoretic mobility shift assays
to investigate the binding of p65 and C/EBPh to their
putative binding sites within the BKV promoter. Nuclear
extracts from cells transfected with plasmids expressing p65
and C/EBPh, either alone or in combination, were prepared
and incubated with a double-stranded oligonucleotide DNA
probe consisting of the NF-nB and C/EBPh binding
sequences of BKV. The binding reactions were performed
in the presence of specific antibodies that recognize p65, C/
EBPh, and a control normal antibody to establish the
presence of p65 and C/EBPh in the DNA-protein complex.
As shown in Fig. 2 (panel A), a distinct band appeared
when extract from p65-transfected cells was incubated with
probe (compare lanes 2 and 3). The observed band
disappeared upon the addition of anti-p65 antibody and a
new slower migrating band on the top of the gel (supershift
band) was detected, indicating that the observed DNA-
protein complex contained p65 (lane 5). The addition of
control antibody (normal preimmune sera) had no effect on
Fig. 1. Transcription regulation of BKV promoters by p65 and C/EBPh. (A) Regulatory region of BKV Dunlop depicting palindrome (Pal), two inverted
repeats (IR1, IR2), 20-bp AT-rich region (A/T), the three direct repeats (P), a single 63 base pair block (S) (Deyerle and Subramani, 1988). The arrow indicates
major early transcription start site. The filled oval and rectangle show the position of C/EBPh and NF-nB binding sites as identified by MatInspector,
respectively. Open ovals point to the location of known binding sites for NF-1, AP-1, and Sp1. (B) Effect of p65 and C/EBPh on transcriptional activity of the
BKVE promoter. A 520 nucleotide region corresponding to +387 to +5020 of the BKV Dunlop promoter/enhancer was cloned in the early orientation into the
BamHI site of pBLCAT3. CV-1 cells were transfected with the indicated amounts of expression vectors CMV-p65 (1 Ag) (lane 2), CMV-C/EBPh (0.01, 0.05,
0.25, and 1.25 Ag) (lanes 3–6, respectively), and BKVE-CAT (1 Ag) using the Fugene6 (Roche Molecular Biochemicals, Indianapolis, IN) transfection reagent
at a 2:1 Fugene6:DNA ratio. In lanes 7–10, cells were transfected with 1.0 Ag of CMV-p65 and 0.01, 0.05, 0.25, and 1.25 Ag of CMV-C/EBPh, respectively.
Total DNA in all transfections was held constant by the addition of empty CMV vector. After 48 h, protein extracts were prepared and the chloramphenicol
acetyltransferase activity was determined as described (Coyle-Rink et al., 2002). The results are shown as fold induction, with the chloramphenicol
acetyltransferase activity of the reporter alone arbitrarily set as 1.0. The results shown represent two separate transfection experiments, and the numbers indicate
fold activationF standard deviation. (C) Effect of p65 (1.0 Ag) and C/EBPh (0.05 Ag) on the BKVL promoter by the method described in panel B. The reporter
plasmid contains the BKV genome for the +387 to +5020 fragment in the late orientation cloned at the 5V end of the CAT gene in pBLCAT3. The results shown
represent two separate transfection experiments, and the numbers indicate fold activation F standard deviation.
Rapid Communication 3the electrophoretic mobility of the p65 complex (lane 4).
Incubation of extract from C/EBPh-transfected cells with
the DNA probe showed a series of faint bands that appeared
as a smear (lane 6, shown by a bracket). The addition of
anti-C/EBPh to the binding mixture cleared the appearance
of the smear and caused the formation of a distinct band
(lane 8), suggesting the presence of C/EBPh in the
observed smear. Again, the addition of the control
(preimmune sera) to the binding mixture had no effect on
the electrophoretic mobility of the observed smear bands,
pointing to the specificity of the observed supershift
complex in lane 8. Both p65 and C/EBPh, once co-
expressed in the cells, showed the ability to bind to their
DNA motif (lanes 9 to 13), with no clear evidence of a
p65:C/EBPh-containing DNA complex. Results from West-ern blot analysis verified the integrity of C/EBPh and p65
in the extract from the transfected cells (Fig. 2B). In an
alternative approach, we next performed mobility shift
assays using in vitro synthesized p65 and C/EBPh. When
incubated with the DNA probe, p65 formed a complex with
greater efficiency than C/EBPh (Fig. 2C). Interestingly, in
the presence of p65, the intensity of the band corresponding
to C/EBPh was decreased and again no evidence for the
formation of p65:DNA:C/EBPh complex was observed
(Fig. 2C). To investigate the possibility of an off-DNA
physical interaction between p65 and C/EBPh, we per-
formed affinity chromatography with glutathione-S-trans-
ferase (GST) fusion proteins as bait. Results from this
experiment showed that C/EBPh shows binding affinity to
GST-p65, but not GST. Interestingly, a strong binding of C/
Rapid Communication4EBPh with the p50 subunit of NF-nB was noted (Fig. 2D).
Reciprocal GST pull-down using GST-C/EBPh further
verified the association of p65 and C/EBPh (data not
shown). These data are in accord with the previous
observation demonstrating direct physical interaction
between Rel proteins and b-ZIP domain of C/EBP (Stein
et al., 1993).To better understand the importance of the interaction of
C/EBPh and NF-nB with their DNA motif in the regulation
of BKVE gene transcription, we performed mobility shift
assays with oligonucleotide DNA probes containing muta-
tions in either NF-nB or C/EBPh motifs. Further, similar
mutations were introduced in the BKVE reporter construct
and their activities were evaluated. As seen in Fig. 3A, the
Rapid Communication 5oligonucleotide with the mutated C/EBPh binding site
showed the ability to interact with p65, suggesting no major
contribution from C/EBPh in the binding of p65 to its DNA
motif. Similarly, C/EBPh associated with its DNA motif in
the oligonucleotide with the mutated NF-nB binding site in
the presence and absence of p65 (Fig. 3B). As before, the
addition of specific antisera supershifted p65 and C/EBPh-
specific bands, verifying the presence of these proteins in
the shifted complexes. We also noted that the binding of C/
EBPh to the NF-nB mutant probe was reduced in the
presence of p65, which points to the ability of in vitro
synthesized p65 to abrogate C/EBPh binding to the wild-
type probe (see Fig. 2C). Hence, although p65 and C/EBPh
have the ability to bind to the BKV promoter, it seems that
their interactions are not mutually exclusive. Results from
transfection assay revealed that mutation in the C/EBPh
binding site did not result in loss of p65 or p65:C/EBPh-
dependent activation of BKVE promoter (Fig. 3C). How-
ever, mutation in the NF-nB site caused loss of p65- and
p65:C/EBPh-dependent transcription of the viral early
promoter (Fig. 3D). These observations ascribe an important
role for the NF-nB binding site on the ability of p65 to
stimulate transcription of the BKVE promoter and to
cooperate with C/EBPh to further enhance p65-mediated
activation of the viral promoter. To further investigate
possible cooperativity between p65 and C/EBPh in binding
to the BKV promoter, we performed competition mobility
shift assays using [32P]-labeled oligonucleotide DNA probe
containing wild-type NF-nB/C/EBPh binding sites in the
absence or presence of unlabeled wild-type, mutant NF-nB,
and mutant C/EBPh DNA competitors at 10- and 100-fold
molar in excess compared to that of the probe. As seen in
Fig. 3E, from the intensity of the band corresponding to the
p65:DNA complex, C/EBPh may not significantly affect the
level of interaction of p65 with the NF-nB site (compares
lanes 2 and 9). Also, from the competition it is evident that
the oligonucleotide with no C/EBPh binding site but with
an intact NF-nB binding site (?C) effectively competed for
the association of p65 with the wild-type probe (lanes 7, 8,
14, and 15). Conversely, the competitor DNA which is
devoid of an NF-nB binding site, but maintains the intact C/Fig. 2. Interaction of p65 and C/EBPh with DNA and with each other. (A) Bin
transfected alone or in combination with CMV-p65 (25 Ag) and CMV-C/EBPh (25
after transfection, nuclear extracts were prepared as described (Andrews and Faller
labeled double-stranded oligonucleotide probe containing the NF-nB/C/EB
TTGCAAAAATTGCAAAAGAATAGGGATTCCCCAAATA-3V) as previously d
incubated with specific antisera (sc-373 and sc-7692 [Santa Cruz Biotechnology] f
positions of p65- and C/EBPh-specific bands are indicated by an arrow and brac
indicated with an asterisk. (B) Western blot analysis of the nuclear extracts from
plus CMV-C/EBPh (lane 4) transfected cells. The numbers on the side represent t
analyzed by SDS–PAGE and detected with p65- and C/EBPh-specific antibodies.
Non-radiolabeled IVT-p65 and -C/EBPh were synthesized using the TnT Quick C
products was confirmed by Western blot (not shown). 1 AL IVT-p65 and 0.5 (lanes
combination with 50,000 cpm of the NF-nB/C/EBPh probe as in 2A. (D) GST aff
GST-p65, but not GST. GST fusion proteins were produced as previously descr
synthesized in vitro as described panel B, in the presence of [35S]-methionine. 5 Ag
C/EBPh in LB-150 buffer as previously described (Gallia et al., 1999) and separEBPh site, did not affect the binding of p65 to the wild-type
probe (lanes 5, 6, 12, and 13).
The results from site-directed mutagenesis of the BKVE
promoter are reminiscent of a recent study that showed that
the b-ZIP domain of C/EBPh substitutes for full-length C/
EBPh to mediate transcription of the interleukin-6 (IL-6)
promoter through an NF-nB site (Hu et al., 2000). Translation
of the C/EBPhmRNA has the potential to produce both a ~40
kDa and 35 kDa full-length isoforms, termed C/EBP-LAP*
and C/EBPh-LAP (liver-enriched activating protein), respec-
tively, and a 20-kDa isoform, termed LIP (liver-enriched
inhibitory protein) (Descombes and Schibler, 1991). LIP,
which is regarded as a dominant-negative isoform of C/
EBPh, also substitutes for C/EBPh to activate transcription
from the IL-6 promoter (Hu et al., 2000). Next, we sought to
determine if a similar mechanism of activation is responsible
for synergism between C/EBPh and p65 in transactivation of
the BKVE promoter. To compare the effect of the LAP and
LIP isoforms with C/EBPh on BKVE transcription, the
BKVE reporter was transfected with p65 alone or in
combination with plasmids expressing C/EBPh or only the
LAP or LIP isoforms (Fig. 4A). Expression of each protein in
transfected cells was first verified by Western blot (Fig. 4B).
While co-production of p65 and C/EBPh (which expressed
both the LAP and LIP isoforms) caused a synergistic
activation, surprisingly, the 35-kDa LAP isoform failed to
result in synergistic activation of BKVE transcription.
Curiously, co-expression of LIP with p65 was able to
cooperate with p65 and stimulate BKVE gene transcription
(Fig. 4C). These observations suggest that the synergism
between p65 and C/EBPh is mediated by the region of C/
EBPh that spans the C-terminal b-Zip domain of C/EBPh
between residues 132 and 276. Furthermore, it is also evident
that the region between amino acid residues 22–132 can
negatively impact upon the synergism between residues 132
and 276, and that this effect can be inhibited by the extreme
N-terminal of C/EBPh positioned between residues 1 and 22.
To further investigate the DNA sequence requirement for
the synergism between LIP and p65, we performed co-
transfection experiments using mutant BKVE promoter
constructs with either no binding site for NF-nB (?N) ording of p65 and C/EBPh to the NF-nB/C/EBPh probe. COS-7 cells were
Ag) by the calcium phosphate method (Graham and van der Eb, 1973). 48 h
, 1991). 10 Ag of nuclear extract was incubated with 50,000 cpm of a [32P]
Ph sequence from the BKV Dunlop promoter/enhancer region (5V
escribed (Safak et al., 1999). For supershift experiments, extracts were
or p65 and C/EBPh, respectively) for 15 min prior to addition of probe. The
kets, respectively. The position of a non-specific band in lanes 3 and 4 is
control (lane 1), CMV-p65 (lane 2), CMV-C/EBPh (lane 3), and CMV-p65
he positions of the molecular weight markers. 10 Ag of nuclear extract was
(C) Band shift assay using in vitro synthesized p65 and C/EBPh proteins
oupled Transcription/Translation System (Promega), and the quality of IVT
2 and 4), and 1 AL IVT-C/EBPh (lanes 3 and 4) were incubated alone or in
inity chromatography showing the binding of IVT-C/EBPh to GST-p50 and
ibed (Gallia et al., 1999). CMV-p65, CMV-P50, and CMV-C/EBPh were





Rapid Communication6C/EBPh (?C). As shown in Fig. 4D, removal of the NF-nB
motif from the BKVE promoter completely abrogated the
effect of p65 and the synergism between LIP and p65 uponFig. 3. Physical and functional interaction of p65 and C/EBPh. Mobility shift a
sites. Nuclear extracts from COS cells transfected with CMV-p65 and/or C
fragment containing mutant C/EBPh (5V-TTGCAAAAATTGTAAAAGAATA
CAAAAGAATAGGGATTGACCAAATA-3V), shown in panels A and B, respect
as described in Fig. 2A. The positions of p65, C/EBPh, supershifted complexe
BKVE-CAT (1 Ag) construct containing a mutation in the C/EBPh (C) or
combination with CMV-p65 (1 Ag) and CMV-C/EBPh (0.01 Ag) as described in
mutagenesis of the NF-nB and C/EBPh binding sites using the following olig
directed mutagenesis kit: for DN 5V-CAAAAGAATAGGGATTGACCAAATAGT
The mutant constructs were examined by direct sequencing to verify their inte
acetyltransferase activity of the reporter alone arbitrarily set as 1.0. Error bars re
(E) Competition mobility shift assay with wild-type NF-nB and C/EBPh prob
transfected with CMV-p65, CMV-C/EBPh, or both were incubated with wild-ty
type (wt), mutant NF-nB (DN), and mutant C/EBPh (DC) competitors at eithBKV transcription. Again, removal of the C/EBPh binding
site had no significant effect on p65-dependent BKVE
transcription and cooperation with LIP.ssay with probes containing mutated C/EBPh (A) or NF-nB (B) binding
MV-C/EBPh were prepared and incubated with double-stranded DNA
GGGATTCCCCAAATA-3V) or mutant NF-nB (5V-TTGCAAAAATTG-
ively. Control and specific antisera were included in the reaction mixture
s, and free probe are shown on the sides of each panel. (C and D) The
NF-nB (D) binding sites was transfected into CV-1 cells alone or in
legend to Fig. 1B. BKVE-CAT was used as the substrate for site-directed
onucleotide primers and the PCR-based QuikChangeII (Stratagene) site-
TTTGC-3V; for DC 5V-AAATTGCAAAAATTGTAAAAGAATAGGGA-3V.
grity. The results are shown as fold induction, with the chloramphenicol
present standard deviation for three independent transfection experiments.
e and wild-type or mutant competitors. Nuclear extracts from COS cells
pe NF-nB/C/EBPh probe in the presence or absence of unlabeled wild-
er 10- or 100-fold excess concentrations.
Fig. 4. (A) Diagram showing both 40 kDa C/EBPh-LAP (designated C/EBPh-LAP*), C/EBPh LAP (35 kDa), and LIP (20 kDa) isoforms (a gift from Ueli
Schibler, Geneva, Switzerland) used in the transfection experiments in B and C. (B) Monkey kidney (COS-7) cells were transfected as described in Fig. 2 with
expression vectors for C/EBPh, LAP, and LIP. 48 h after transfection, nuclear extracts were prepared and analyzed by Western blot with C/EBPh-specific
antisera (sc-7692 from Santa Cruz). (C) CV-1 cells were transfected BKVE-CAT alone or with the indicated combinations of CMV-p65 (1 Ag), CMV-C/EBPh
(0.01 Ag) CMV-LAP (0.01 Ag), and CMV-LIP (0.01 Ag). Error bars represent standard deviation for two independent transfection experiments. (D) CV-1 cells
were transfected with BKVE-CAT, BKVE-CAT NF-nB mutant, or BKVE-CAT C/EBPh mutant reporters alone or with the indicated combinations of CMV-p65
(1 Ag), CMV-C/EBPh (0.01 Ag), and CMV-LIP (0.01 Ag). Numbers indicate fold activation F standard deviation.
Rapid Communication 7The results presented in this communication identify and
characterize binding sites for the inducible transcription
factors NF-nB and C/EBPh in the early leader region of the
BKVE promoter. Expression of the p65 subunit of NF-nB can
significantly activate transcription of the BKVE promoter.
Furthermore, while expression of C/EBPh alone had noeffect on BKVE transcription, co-expression of C/EBPhwith
p65 dramatically augmented p65-dependent activation of
BKVE transcription. The results from functional analysis
using site-directed mutagenesis of the putative NF-nB and C/
EBPh binding sites show that C/EBPh augments p65-
dependent transcription of the BKVE promoter in a manner
Rapid Communication8independent of the C/EBPh DNA-binding site, even though
both p65 and C/EBPh were shown to bind to the NF-nB and
C/EBPh motif, respectively, in mobility shift assays.
Previous studies have relied on techniques such as
DNaseI protection and linker scan analyses to identify
regions of the BKV promoter/enhancer which are bound by
cellular proteins and/or are important for efficient BKVE
transcription. These studies led to the discovery of binding
sites for several transcription factors including NF-1, AP-1,
and Sp1 (Cassill et al., 1989; Deyerle and Subramani, 1988;
Markowitz and Dynan, 1988). The use of MatInspector has
allowed us to further characterize the BKVE promoter by
identifying putative binding sites for the transcription
factors NF-nB and C/EBPh, both of which are induced by
a variety of stimuli which may not be apparent in assays
which use nuclear extracts and functional assays from
unstimulated cells.
NF-nB family members have been shown to cooperate
with C/EBPh to synergistically activate transcription of
several cellular genes including serum amyloid A, inter-
leukin-6, interleukin-8, inducible nitric oxide synthase, and
intercellular adhesion molecule-1 (Catron et al., 1998; Hu et
al., 2000; Matsusaka et al., 1993; Ray et al., 1995; Sakitani
et al., 1998). In most cases, synergistic gene activation
requires functional binding sites for both families of
transcription factors. However, in one study, it was shown
that the 20-kDa isoform of C/EBPh, LIP, which lacks the
amino-terminal activation domain, can substitute for the 35-
kDa isoform of C/EBPh to activate the IL-6 and MCP-1
promoters in response to lipopolysaccharide, which, in the
case of the IL-6 promoter, depended completely on an intact
NF-nB binding site (Hu et al., 2000). Similarly, in this study,
we have found that LIP can functionally interact with p65 to
enhance p65-dependent transcription of the BKVE promoter
and that the interaction between p65 and LIP only requires
an intact NF-nB binding site.
As noted earlier, the presence of the NF-nB and C/EBPh
binding sites in the promoter/enhancer region of the various
BKV strains highlights the potential significance of this
conserved region in BKV transcription and/or replication.
Although we cannot rule out the possibility that p65 and C/
EBPh contribute to mRNA stabilization, the binding of p65
and C/EBPh to their respective motifs and their synergistic
effect on the BKVE promoter point to their potential
involvement in BKV gene expression and viral reactivation.
We are currently investigating the mechanism(s) by which
p65 mediates BKVE gene transcription, including the
possibility of stimulation of elongation and/or recruitment
of chromatin remodeling factors such as p300, which have
been shown to be important for p65-dependent stimulation of
transcription of the HIV-1 long-terminal repeat and inter-
leukin-6 gene transcription, respectively (Vanden Berghe et
al., 1999; West et al., 2001). While our results demonstrate
that overexpression of C/EBPh and p65 in cells causes
enhanced cooperativity between these two proteins upon the
BKVE promoter activation, presumably due to associationwith the NF-nB motif, one can also envision an alternative
pathway by which this activation regulates BKV gene
expression by altering expression of other cellular genes. In
this study we utilized transfection assay to demonstrate the
functionality of the NF-nB and C/EBPh binding sites in
regulating BKV promoter activity. Our data suggest the
ability of both C/EBPh and p65 to cooperate with each other
to enhance BKVE gene expression. While the importance of
this observation in the pathogenesis of BKV induced kidney
disease and the reactivation of BKV upon immunosuppres-
sion remains to be seen, one can speculate that alteration of
cytokines and immunomodulators that affect the level of
expression and activity of NF-nB, C/EBPh, and other factors
can promote the activation of the BKVE promoter. Our
preliminary data have shown that treatment of cells with
TNFa and other NF-nB inducers such as PMA results in
enhanced binding of NF-nB to BKV DNA and activation of
the BKV promoter in cells, suggesting that our observations
may be physiologically relevant. Future studies using
cytokine array to determine the cytokines that are upregulated
during the course of BKV reactivation and studying their
downstream signaling factors should provide more insight
into the pathogenesis of BKV associated disorders.
In conclusion, the results from this study provide new
insights into the potential mechanism(s) by which BKV may
reactivate from latency. It would be interesting to assess
whether or not NF-nB and/or C/EBPh are activated by
allogeneic stimulation after kidney transplantation, and if so,
does activation of either NF-nB or C/EBPh correlate with
BKV nephropathy. We are currently testing this possibility
on renal biopsy samples from renal transplant recipients.Acknowledgments
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